Mfg. of: Bulk Drugs, Drug Intermediates & Speciality Chemicals



Date: 23rd May, 2023

To,
The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services
P.J Towers, Dalal Street,
Mumbai 400001
Scrip Code: 540359

<u>Sub: Intimation of Board Meeting in compliance with Reg. 29 read with Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements)</u> Regulations, 2015.

Dear Sirs,

With reference to the captioned subject, we would like to inform you that the Meeting of the Board of Directors of Parmax Pharma Limited will be held on Tuesday, 30th May, 2023 at 12.30 PM inter alia to consider, approve the Audited Financial Results of the quarter and Financial year ended 31st March, 2023 and to discuss any other matter with the permission of Board.

Under our letter dated 31st March, 2023, we had communicated closure of trading window in respect of the Company with immediate effect till 48 hours after public announcement of the Audited Financial Results for the quarter and Financial year ended 31st March, 2023. Consequently, the Trading Window will remain closed till 1st June, 2023.

You are requested to kindly take the above information on your record.

Thanking you,

Yours faithfully,

For Parmax Pharma Limited

Yash Vora Company Secretary